Arcturus Therapeutics Holdings (ARCT) Profit After Tax (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) reported Profit After Tax of -$27.0 million for Q1 2026, down 91.56% on a YoY basis from -$319.5 million in Q1 2025, and up 7.27% quarter-over-quarter from -$29.1 million in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) Profit After Tax (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings has reported Profit After Tax for 9 years, with the latest figure at -$27.0 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax fell 91.56% year-over-year to -$27.0 million; the trailing twelve-month figure through Mar 2026 stood at -$78.7 million (down 15.35% YoY), and the FY2025 full-year result was -$65.8 million, up 18.73% from the prior year.
- Profit After Tax for Q1 2026 stood at -$27.0 million, up from -$29.1 million in the prior quarter.
- The five-year high for Profit After Tax was $117.3 million in Q4 2022, with the low at -$52.6 million in Q2 2023.
- Historically, Profit After Tax has averaged -$11.4 million across 5 years, with a median of -$17.2 million in 2024.
- Annual changes were most pronounced in 2022 — Profit After Tax soared 403.51% — and 2024, when it tumbled 156.3%.
- Arcturus Therapeutics Holdings' Profit After Tax stood at $117.3 million in 2022, then tumbled by 109.98% to -$11.7 million in 2023, then sank by 156.3% to -$30.0 million in 2024, then rose by 3.09% to -$29.1 million in 2025, then gained by 7.27% to -$27.0 million in 2026.
- The last three Profit After Tax figures came in at -$27.0 million (Q1 2026), -$29.1 million (Q4 2025), and -$13.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.90 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -753,254.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.74 Mn |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - | -26.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.96 Mn |
| Dec 31, 2025 | -29.08 Mn |
| Sep 30, 2025 | -13.45 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -14.08 Mn |
| Dec 31, 2024 | -30.01 Mn |
| Sep 30, 2024 | -6.90 Mn |
| Jun 30, 2024 | -17.22 Mn |
| Mar 31, 2024 | -26.82 Mn |
| Dec 31, 2023 | -11.71 Mn |
| Sep 30, 2023 | -16.22 Mn |
| Jun 30, 2023 | -52.55 Mn |
| Mar 31, 2023 | 50.75 Mn |
| Dec 31, 2022 | 117.35 Mn |
| Sep 30, 2022 | -35.27 Mn |
| Jun 30, 2022 | -21.56 Mn |
| Mar 31, 2022 | -51.17 Mn |
| Dec 31, 2021 | -38.66 Mn |
| Sep 30, 2021 | -54.08 Mn |
| Jun 30, 2021 | -54.58 Mn |